Pfizer (PFE) Assets Average (2009 - 2026)
Pfizer (PFE) posted quarterly Assets Average of $208.0 billion for Q1 2026, down 1.19% year-over-year from $210.5 billion in Q1 2025, and little changed quarter-over-quarter from $208.4 billion in Q4 2025.
Pfizer (PFE) Assets Average (2009 - 2026) Analysis & Trends
Pfizer (PFE) has reported Assets Average for 18 consecutive years, with $208.0 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average fell 1.19% year-over-year to $208.0 billion; the TTM figure through Mar 2026 stood at $208.0 billion (down 1.19% YoY), while the FY2025 annual figure was $210.5 billion, down 2.65% from the prior year.
- Assets Average steadied at $208.0 billion in Q1 2026 per PFE's latest filing, from $208.4 billion in the prior quarter.
- Across five years, Assets Average topped out at $224.0 billion in Q1 2024 and bottomed at $118.2 billion in Q3 2022.
- Historically, Assets Average has averaged $188.1 billion across 5 years, with a median of $207.4 billion in 2025.
- Annual changes were most pronounced in 2024 — Assets Average jumped 65.58% — and 2025, when it declined 6.04%.
- Pfizer's Assets Average stood at $119.1 billion in 2022, then advanced by 13.31% to $134.9 billion in 2023, then soared by 60.28% to $216.2 billion in 2024, then retreated by 3.64% to $208.4 billion in 2025, then fell by 0.18% to $208.0 billion in 2026.
- Business Quant data shows PFE's Assets Average at $208.0 billion in Q1 2026, $208.4 billion in Q4 2025, and $207.4 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 200.98 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 135.79 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 129.24 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 114.92 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 94.07 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 52.82 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 204.57 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 83.80 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 149.95 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 204.57 Bn |
| Mar 29, 2026 | 208.00 Bn |
| Dec 31, 2025 | 208.37 Bn |
| Sep 28, 2025 | 207.41 Bn |
| Jun 29, 2025 | 207.06 Bn |
| Mar 30, 2025 | 210.51 Bn |
| Dec 31, 2024 | 216.24 Bn |
| Sep 29, 2024 | 217.74 Bn |
| Jun 30, 2024 | 218.55 Bn |
| Mar 31, 2024 | 224.05 Bn |
| Dec 31, 2023 | 134.92 Bn |
| Sep 30, 2023 | 131.50 Bn |
| Jul 2, 2023 | 208.08 Bn |
| Apr 2, 2023 | 196.50 Bn |
| Dec 31, 2022 | 119.07 Bn |
| Sep 30, 2022 | 118.21 Bn |
| Jul 3, 2022 | 189.57 Bn |
| Apr 3, 2022 | 182.42 Bn |
| Dec 31, 2021 | 113.67 Bn |
| Oct 3, 2021 | 108.13 Bn |